Vis enkel innførsel

dc.contributor.authorHaaland, Ingvild
dc.contributor.authorHjelle, Sigrun Margrethe
dc.contributor.authorReikvam, Håkon
dc.contributor.authorSulen, André
dc.contributor.authorRyningen, Anita
dc.contributor.authorCormack, Emmet Mc
dc.contributor.authorBruserud, Øystein
dc.contributor.authorGjertsen, Bjørn Tore
dc.date.accessioned2021-10-14T07:53:43Z
dc.date.available2021-10-14T07:53:43Z
dc.date.created2021-05-03T16:41:45Z
dc.date.issued2021
dc.identifier.citationHaaland, I., Hjelle, S. M., Reikvam, H., Sulen, A., Ryningen, A., McCormack, E., Bruserud, Ø., & Gjertsen, B. T. (2021). p53 protein isoform profiles in AML: Correlation with distinct differentiation stages and response to epigenetic differentiation therapy. Cells, 10(4).en_US
dc.identifier.issn2073-4409
dc.identifier.urihttps://hdl.handle.net/11250/2803687
dc.description.abstractp53 protein isoform expression has been found to correlate with prognosis and chemotherapy response in acute myeloid leukemia (AML). We aimed to investigate how p53 protein isoforms are modulated during epigenetic differentiation therapy in AML, and if p53 isoform expression could be a potential biomarker for predicting a response to this treatment. p53 full-length (FL), p53β and p53γ protein isoforms were analyzed by 1D and 2D gel immunoblots in AML cell lines, primary AML cells from untreated patients and AML cells from patients before and after treatment with valproic acid (VPA), all-trans retinoic acid (ATRA) and theophylline. Furthermore, global gene expression profiling analysis was performed on samples from the clinical protocol. Correlation analyses were performed between p53 protein isoform expression and in vitro VPA sensitivity and FAB (French–American–British) class in primary AML cells. The results show downregulation of p53β/γ and upregulation of p53FL in AML cell lines treated with VPA, and in some of the patients treated with differentiation therapy. p53FL positively correlated with in vitro VPA sensitivity and the FAB class of AML, while p53β/γ isoforms negatively correlated with the same. Our results indicate that p53 protein isoforms are modulated by and may predict sensitivity to differentiation therapy in AML.en_US
dc.language.isoengen_US
dc.publisherMDPIen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.subjectp53 protein isoformsen_US
dc.subjectacute myeloid leukemiaen_US
dc.subjectdifferentiation therapyen_US
dc.subjectFrench–American– British (FAB) classificationen_US
dc.subjectvalproic aciden_US
dc.subjectall-trans retinoic aciden_US
dc.titlep53 Protein Isoform Profiles in AML: Correlation with Distinct Differentiation Stages and Response to Epigenetic Differentiation Therapyen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.rights.holder© 2021 by the authorsen_US
dc.subject.nsiVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762en_US
dc.source.volume10en_US
dc.source.journalCellsen_US
dc.identifier.doi10.3390/cells10040833
dc.identifier.cristin1907848
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal